Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.21.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating expenses:    
Research and development $ (2,451) $ (9,743)
General and administrative (3,396) (3,151)
Total operating expenses (5,847) (12,894)
Operating loss (5,847) (12,894)
Interest expense, net (2,952) (2,596)
Financing transaction costs   (2,130)
Adjustments to fair value of derivatives (90,103) 1,679
Other income / (expense), net 41 (38)
Total other expense (93,014) (3,085)
Loss before income taxes (98,861) (15,979)
Income tax expense (60) (121)
Net loss and comprehensive loss (98,921) (16,100)
Net loss attributable to ordinary shareholders $ (98,921) $ (16,100)
Net loss per share attributable to ordinary shareholders – basic and diluted $ (0.81) $ (1.08)
Weighted average ordinary shares outstanding – basic and diluted 121,549,083 14,868,973